The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.
 
Tahlia Scheinberg
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - patent on PCPro - a plasma lipidomic biomarker for patients with mCRPC
Travel, Accommodations, Expenses - Bayer
 
James Kench
No Relationships to Disclose
 
Peter Ferguson
No Relationships to Disclose
 
Sarah Sutherland
No Relationships to Disclose
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Kate Mahon
No Relationships to Disclose
 
Phillip Stricker
No Relationships to Disclose
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Henry Woo
Stock and Other Ownership Interests - Health Analytics Holdings Pty Ltd
Consulting or Advisory Role - Ferring
Speakers' Bureau - Astellas Pharma; Bayer; Boston Scientific; Olympus
Research Funding - Astellas Oncology; Boston Scientific; Janssen
 
Ruban Thanigasalam
No Relationships to Disclose
 
Nariman Ahmadi
No Relationships to Disclose
 
Gavin Marx
No Relationships to Disclose
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Shomik Sengupta
Employment - Eastern health
Honoraria - Mundipharma (Inst)
 
Scott Leslie
No Relationships to Disclose
 
Margaret Centenera
No Relationships to Disclose
 
Lisa Butler
Patents, Royalties, Other Intellectual Property - Patents awarded for novel biomarkers to improve prostate cancer diagnosis: PCT/AU2014/000612 Priority : AU 2013902141. [National numbers: Australia 2014280846 Published 24.12.2015; European Patent Office 2014810393 lodged 11.01.2016; Japan 2016518800 lod
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology; Pfizer